

# Relation of obesity with serum 25 hydroxy vitamin D3 levels in type 2 diabetic patients

Ahmet Cimbeç, Gül Gürsoy<sup>1</sup>, Nazlı Gülsoy Kirnap, Yaşar Acar, Zuhal Kiliç, Fatih Güngör, Işıl Özdeş

Department of Internal Medicine, Ankara Education and Research Hospital, Ankara, <sup>1</sup>Department of Internal Medicine, University of Kafkas, Kars, Turkey

**Background:** Hypovitaminosis D is associated with diabetes mellitus (DM). Aim of our study was to determine the relation of obesity with vitamin D levels in type 2 diabetic patients. **Materials and Methods:** We examined 101 type 2 diabetic patients and made a correlation analysis in all parameters. Then we classified our diabetics according to their body-mass indices and compared their 25 hydroxy vitamin D3 levels. **Results:** We found negative correlation between 25O HD and body mass index (BMI) ( $P < 0.001$ ,  $r = -0.23$ ). When we classified our diabetics according to their body mass indices as normal, overweight and obese, and compared their 25 hydroxy vitamin D3 levels, we determined that in every BMI group 25 hydroxy vitamin D levels were not found to be significantly different. **Conclusion:** These results suggest that at least in a Turkish population with type 2 DM vitamin D levels are low and correlate with BMI, but when vitamin D levels are so low, as obesity worsens vitamin D levels does not lessen.

**Key words:** Obesity, type 2 diabetes mellitus, vitamin D

## INTRODUCTION

Hyperglycemia was shown to be independently associated with low vitamin D levels.<sup>[1]</sup> The relationship between vitamin D deficiency and risk of diabetes both type 1<sup>[2-6]</sup> and type 2<sup>[7-10]</sup> has also been reported in the literature.

A high prevalence of hypovitaminosis D was noted in diabetics.<sup>[11-16]</sup> One of the reasons for this is stated to be obesity besides diet, lack of sun exposure, renal impairment and genetic predisposition. Studies have suggested vitamin D insufficiency is associated with increased obesity.<sup>[17-26]</sup>

It has been shown that in Turkey vitamin D deficiency is an important problem.<sup>[27-30]</sup> There have been rare studies about obesity and vitamin D levels<sup>[26,27,31]</sup> in Turkish population. Aim of this study was to show the relation of obesity with vitamin D levels in type 2 diabetic patients.

## MATERIALS AND METHODS

### Patients

A total of 101 type 2 diabetes mellitus (T2DM) patients, aged from 30-80 years, were recruited from the outpatient clinic of Ankara Education and Research Hospital from January 2011 to February 2011. Sixty one of them were female (61%), 40 of them were male (29%).

We excluded patients with chronic diseases of renal and liver, skin disorders, malabsorption, inflammatory bowel or celiac disease (in history or nowadays), and once taking medications that may interfere with serum levels of 25 hydroxy vitamin D (25 (OH) D).

After detailed physical examination, we measured body weight and height of all the patients. Waist was measured when fasting, in standing position halfway between costal edge and iliac crest, whereas hip was measured at the greatest circumference around the buttocks, by a non-elastic measure. We calculated body mass index (BMI) as weight in kilograms divided by the square of height in meters ( $\text{kg}/\text{m}^2$ ).

Blood was withdrawn after 12 h of overnight fasting, at 08.30 a.m., for fasting plasma glucose (FPG), hemoglobin A1c, fasting insulin (FI), serum total and high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), creatinine, calcium (Ca), phosphorous (P), parathyroid

### Access this article online

Quick Response Code:	Website: www.journals.mui.ac.ir/jrms
	DOI: ***

**Address for correspondence:** Dr. Gül Gürsoy, Department of Internal Medicine, Ankara Education and Research Hospital, Ankara, Turkey.  
Email: gulgursoyyener@yahoo.com

**Received:** 18-01-2012; **Revised:** 20-09-2012; **Accepted:** 21-10-2012

hormone (PTH), thyroid stimulating hormone (TSH), C-reactive protein (CRP), homocysteine (Hcy), and 25 (OH) D levels.

An indirect measure of insulin resistance was calculated from the fasting plasma insulin ( $\mu\text{unit/ml}$ )  $\times$  FPG (mmol/l)/22.5 formula as homeostasis model assessment-insulin resistance.

Systolic and diastolic blood pressure were measured after a 5 min rest in the semi-sitting position with a sphygmomanometer. Blood pressure was determined at least three times at the right upper arm, and the mean was used in the analysis.

### Laboratory methods

Plasma glucose, total cholesterol, TG and HDL-C, Ca, P concentrations were determined by enzymocalorimetric spectrophotometric method in a Roche/Hitachi molecular PP autoanalyser. Low density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (LDL: Total cholesterol-HDL-TG/5). Insulin was measured by DRG Diagnostics (DRG Instruments GmbH, Germany) ELISA kits and FI was measured by TOSOH G7 HPLC system. PTH and TSH were determined with Advia Sentor XP device by chemoluminescence method. High sensitivity CRP was measured by immunofluorescence tests by Beckman-Cutler device. Hcy concentrations were determined according to the method of HPLC using Agilent 1100 device. For the measurements of 25 (OH) D, Waters LC-MS/MS device liquid chromatography mass spectrometry was used.

### Methods

We made correlation analysis between parameters in type 2 diabetics, then made the comparison of 25 (OH) D levels in three BMI groups. We grouped the patients as normal (BMI < 25 kg/m<sup>2</sup>), overweight (BMI 25-29.9 kg/m<sup>2</sup>), and obese (BMI > 30 kg/m<sup>2</sup>).

This study was performed according to the Helsinki declaration 2008. The local ethics committee approved this study and all the subjects gave written informed consent.

### Statistical analysis

Correlation between variables was calculated by Pearson correlation analysis. For the comparison of the groups ANOVA test was used. Data are presented as mean  $\pm$  SD. A *P* value of < 0.05 was considered as statistically significant.

## RESULTS

We performed the study with 101 T2DM patients. All the demographic and laboratory findings of the patients are presented in Table 1.

When we made correlation analysis in diabetic patients we found positive correlations between 25 (OH) D and creatinin ( $P < 0.05$ ,  $r: 0.18$ ) and negative correlations between 25 (OH) D and BMI ( $P < 0.001$ ,  $r: -0.23$ ), HbA1c ( $P < 0.05$ ,  $r: -0.21$ ), FI ( $P < 0.05$ ,  $r: -0.01$ ), HOMA-IR ( $P < 0.05$ ,  $r: -0.20$ ), PTH levels ( $P < 0.05$ ,  $r: -0.18$ ).

Then we classified our T2DM patients according to their 25 (OH) D levels, as < 12, 12-20 and > 20 ng/ml. All the demographic and laboratory findings of the patients with different 25 (OH) D levels are presented in Table 2. We did not find any difference in any parameters of the patients with different 25 (OH) D levels.

Then we classified our T2DM patients according to their BMI's, as normal (BMI < 25 kg/m<sup>2</sup>), overweight (BMI 25-29.9 kg/m<sup>2</sup>) and obese (BMI > 30 kg/m<sup>2</sup>). We did not notice any statistically significant difference in 25 (OH) D levels of the patients according to their BMI's [Table 3].

## DISCUSSION

Vitamin D status is best assessed by serum 25 (OH) D than 1,25 dihydroxy vitamin D (1,25 (OH)<sub>2</sub>D), because 1,25 (OH)<sub>2</sub>D has a short half life of 15 h and serum

**Table 1: Demographic and laboratory findings of type 2 diabetic patients**

Patients	T2DM (n=101)
Age (year)	55.8 $\pm$ 7.5
BMI (kg/m <sup>2</sup> )	29.8 $\pm$ 4.1
Waist cir. (cm)	97.4 $\pm$ 10.6
Hip cir. (cm)	105.6 $\pm$ 9.5
FBG (mg/dl)	172.1 $\pm$ 68.6
HbA1c (%)	8.2 $\pm$ 2.1
FI ( $\mu$ U/ml)	13.0 $\pm$ 6.4
HOMA-IR	5.4 $\pm$ 3.6
LDL-C (mg/dl)	127.7 $\pm$ 38.4
HDL-C (mg/dl)	44.8 $\pm$ 10.0
TG (mg/dl)	202.9 $\pm$ 23.5
Creatinine (mg/dl)	0.1 $\pm$ 0.04
Ca (mg/dL)	9.4 $\pm$ 0.3
P (mg/dL)	3.3 $\pm$ 0.4
PTH (pg/mL)	53.6 $\pm$ 25.2
TSH ( $\mu$ IU/MI)	1.6 $\pm$ 1.0
CRP (mg/dl)	8.4 $\pm$ 5.3
Hcy ( $\mu$ mol/ml)	11.2 $\pm$ 6.2
SBP (mm Hg)	140.1 $\pm$ 10.1
DBP (mm Hg)	92.6 $\pm$ 11.5
25 (OH) D (ng/ml)	9.9 $\pm$ 7.6

BMI= Body mass index; Waist cir.= Waist circumference; Hip cir.= Hip circumference; FBG= Fasting blood glucose; HbA1c= Hemoglobin A1c; FI= Fasting insulin; HOMA-IR= Homeostasis model assessment index-insulin resistance; LDL-C= Low density lipoprotein cholesterol; HDL-C= High density lipoprotein cholesterol; TG= Triglyceride; Ca: Calcium; P= Phosphorous; PTH= Parathyroid hormone; TSH= Thyroid stimulating hormone; CRP= C-reactive protein; Hcy= Homocysteine; SBP= Systolic blood pressure; DBP= Diastolic blood pressure; 25(OH) D= 25-hydroxy vitamin D. Data are presented as mean $\pm$ SD, NS= Non-significant; T2DM= Type 2 diabetes mellitus

**Table 2: Demographic and laboratory findings of type 2 diabetic patients with different 25-hydroxy vitamin D levels**

25 (OH) D (ng/ml)	<12 ng/ml	12-20 ng/ml	>20 ng/ml	P
Case number	74	20	7	NS
Age (year)	55.3±7.8	39.7±6.0	58.7±7.4	NS
BMI (kg/m <sup>2</sup> )	29.8±4.1	30.0±3.0	29.5±6.4	NS
Waist cir. (cm)	96.4±9.6	88.4±7.6	92.4±9.7	NS
Hip cir. (cm)	105.6±9.5	98.6±8.5	101.6±9.3	NS
FBG (mg/dl)	173.4±71.3	167.4±55.3	192.8±55.8	NS
HbA1c (%)	8.2±2.1	8.3±2.0	8.6±2.1	NS
FI (μU/ml)	13.3±6.9	12.2±4.9	12.1±4.0	NS
HOMA-IR	5.5±4.1	4.8±2.2	5.4±1.5	NS
LDL-C (mg/dl)	129.1±37.6	122.2±41.8	129.4±42.4	NS
HDL-C (mg/dl)	44.6±9.3	43.3±11.6	50.8±11.6	NS
TG (mg/dl)	206.3±126.7	206.0±130.9	158.2±57.7	NS

BMI= Body mass index; Waist cir.= Waist circumference; Hip cir.= Hip circumference; FBG= Fasting blood glucose; HbA1c= Hemoglobin A1c; FI= Fasting insulin; HOMA-IR= Homeostasis model assesment index-insulin resistance; LDL-C= Low density lipoprotein cholesterol; HDL-C= High density lipoprotein cholesterol; TG= Triglyceride. Data are presented as mean±SD NS= Non-significant; 25 (OH) D: 25-hydroxy vitamin D

**Table 3: Comparison of 25-hydroxy vitamin D levels of type 2 diabetes mellitus patients according to their body mass indices**

BMI	Number of patients	25(OH) D levels
Normal	16	13.1±12.7
Over weight	41	8.5±4.7
Obese	44	10.5±6.9
P	NS	

BMI= Body mass index; 25 (OH) D: 25-hydroxy vitamin D; Normal: BMI<25 kg/m<sup>2</sup>, Overweight: BMI 25-29.9 kg/m<sup>2</sup>, Obese: BMI>30 kg/m<sup>2</sup>. Data are presented as mean±SD; NS= Non-significant

concentrations are closely regulated by PTH, Ca, and P.<sup>[32]</sup> Some variation exists related to cutoff values for insufficiency and deficiency due to differences in assay methods and population variations. Normal 25 (OH) D levels should be 30-60 ng/mL.<sup>[32]</sup> Vitamin D insufficiency has been reported to range from levels of 16 to 30 ng/mL.<sup>[33]</sup> Vitamin D deficiency varies from < 11 to < 20 ng/mL<sup>[34,35]</sup> but is generally defined as levels of < 15 ng/mL.<sup>[36]</sup> Whatever value is accepted, it is evident that our diabetics has low values of vitamin D, either totally or when classified according to their BMI's. These results are relevant to those of the studies about DM and decreased serum vitamin D levels.<sup>[11-16]</sup>

People with diabetes are at significant risk for vitamin D insufficiency or deficiency. Reasons for this include limited intake of foods high in vitamin D - less sun exposure due to possible fatigue, obesity or mobility issues - renal impairment, that results in less biologically active vitamin D, since conversion to the active form occurs in the kidneys and genetic predisposition such as polymorphisms of vitamin D binding protein or polymorphisms of CYP2R1 gene (which is necessary to catalyze the formation of the main circulating vitamin D metabolite).<sup>[37]</sup> The last reason may be obesity. More vitamin D is stored in the fatty tissues

and less is biologically active in the serum. Obesity is also associated with inflammation and low vitamin D levels are related to inflammation. Cytokines and other inflammatory agents have been linked to beta cell damage, which then impaires insulin synthesis and secretion. In studies with diabetic mice, high doses of 1,25 (OH) D have been shown to delay the onset of diabetes.<sup>[38]</sup> This active form has been shown to protect beta cell function caused by inflammatory cytokines; interleukine-6 and tumor necrosis factor-alpha.<sup>[39]</sup> Regardless of the possible underlying mechanisms about the relation of vitamin D with obesity, it is relevant to take into account obesity when dealing with low vitamin D levels in diabetes. In our study according to correlation analysis, we found that vitamin D levels were negatively correlated with BMI.

Hypönen *et al.* showed that in their normal, overweight, obese and severely obese subjects serum 25 (OH) D levels decreased with increasing BMI.<sup>[14]</sup> Al-Dagri also determined that BMI was a significant predictor of 25 (OH) D.<sup>[40]</sup> Barchetta *et al.* when classified their patients according to serum 25 (OH) D quartiles, found increasing BMI and waist circumference results, in accordance with decreasing vitamin D levels.<sup>[41]</sup> Finding a negative correlation between vitamin D levels and body-mass indices of our patients, we hoped to find statistically significant difference in 25 (OH) D levels of our normal, overweight and obese diabetic groups. However, we could not be able to demonstrate any difference in 25 (OH) D levels of our patients according to their BMI's. Relatively small sizes of our groups may be a reason. It may also be said that when 25 (OH) D levels were so low obesity markers may not be affected.

It was also surprising that all parameters, including BMI, waist and hip ratios of the patients did not differ when we grouped our patients according to their 25 (OH) D levels. We think that this astonishing result may be due to the small size of the groups. When we looked the levels of 25 (OH) D in the group with > 20 ng/ml, we found that the level of vitamin D was not very high, the mean level was 21.9 ± 22.3 ng/ml. We worry if we can also consider it a reason why there were no differences in BMIs according to varying vitamin D levels.

Present study has some limitations. First, we carried out our study between January and February. Because the primary source of this vitamin is skin production and seasonal variations in vitamin D status is well known we plan to reperform this study in summer. Second, in our type 2 diabetic patients therapy modalities were not mentioned. Third, enlargements of size of the groups are needed. Fourth, as our examination is a cross-sectional one and we randomized our patients from a part of Ankara we cannot apply our results to all the Turkish population.

## CONCLUSION

Grave vitamin D levels were present in type 2 diabetic patients in Turkey. A negative correlation was determined in vitamin D levels and BMI, but as vitamin D deficiency was so low, 25 (OH) D levels did not worsened as obesity increased.

## ACKNOWLEDGMENTS

We thank all the patients.

## REFERENCES

- Hirani V. Relationship between vitamin D and hyperglycemia in older people from a nationally representative population survey. *J Am Geriatr Soc* 2011;59:1786-92.
- Borkar VV, Devidayal, Verma S, Bhalla AK. Low levels of vitamin D in North Indian children with newly diagnosed type 1 diabetes. *Pediatr Diabetes* 2010;11:345-50.
- The EURODIAB Study Group. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. *Diabetologia* 1999;42:51-4.
- Fowlkes JL, Bunn RC, Cockrell GE, Clark LM, Wahl EC, Lumpkin CK, *et al.* Dysregulation of the intrarenal vitamin D endocytic pathway in a nephropathy-prone mouse model of type 1 diabetes. *Exp Diabetes Res.* 2011;2011:269378. (doi: 10.1155/2011/269378).
- Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. *Lancet* 2001;358:1500-3.
- Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-analysis. *Arch Dis Child* 2008;93:512-7.
- Mattila C, Knekt P, Männistö S, Rissanen H, Laaksonen MA, Montonen J, *et al.* Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. *Diabetes Care* 2007;30:2569-70.
- Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, *et al.* Vitamin D and calcium intake in relation to type 2 diabetes in women. *Diabetes Care* 2006;29:650-6.
- Thorand B, Zierer A, Huth C, Linseisen J, Meisinger C, Roden M, *et al.* Effect of serum 25-hydroxyvitamin D on risk for type 2 diabetes may be partially mediated by subclinical inflammation: Results from the MONICA/KORA Augsburg study. *Diabetes Care* 2011;34:2320-2.
- Renzaho AM, Nowson C, Kaur A, Halliday JA, Fong D, Desilva J. Prevalence of vitamin D insufficiency and risk factors for type 2 diabetes and cardiovascular disease among African migrant and refugee adults in Melbourne: A pilot study. *Asia Pac J Clin Nutr* 2011;20:397-403.
- Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. *Diabetes Care* 2001;24(8):1496
- Koshiyama H, Ikeda H, Honjo S, Nakamura Y, Tanaka K, Tsugawa N, *et al.* Hypovitaminosis D is frequent in Japanese subjects with type 2 diabetes. *Diabetes Res Clin Pract* 2007;76:470-1.
- Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. *Diabetologia* 1995;38:1239-45.
- Hyppönen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: The role of obesity. *Diabetes Care* 2006;29:2244-6.
- Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. *Diabetes Res Clin Pract* 1995;27:181-8.
- Tahrani AA, Ball A, Shepherd L, Rahim A, Jones AF, Bates A. The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. *Int J Clin Pract* 2010;64:351-5.
- Pacifico L, Anania C, Osborn JF, Ferraro F, Bonci E, Olivero E, *et al.* Low 25 (OH) D3 levels are associated with total adiposity, metabolic syndrome, and hypertension in Caucasian children and adolescents. *Eur J Endocrinol* 2011;165:603-11.
- Hultin H, Edfeldt K, Sundbom M, Hellman P. Left-shifted relation between calcium and parathyroid hormone in obesity. *J Clin Endocrinol Metab* 2010;95:3973-81.
- Al-Sultan AI, Amin TT, Abou-Seif MA, Al Naboli MR. Vitamin D, parathyroid hormone levels and insulin sensitivity among obese young adult Saudis. *Eur Rev Med Pharmacol Sci* 2011;15:135-47.
- Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, *et al.* Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: Results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). *Diabetes Care* 2011;34:1133-8.
- Ardawi MS, Qari MH, Rouzi AA, Maimani AA, Raddadi RM. Vitamin D status in relation to obesity, bone mineral density, bone turnover markers and vitamin D receptor genotypes in healthy Saudi pre- and post-menopausal women. *Osteoporos Int* 2011;22:463-75.
- Jorde R, Sneve M, Emaus N, Figenschau Y, Grimnes G. Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: The Tromsø study. *Eur J Nutr* 2010;49:401-7.
- Young KA, Engelman CD, Langefeld CD, Hairston KG, Haffner SM, Bryer-Ash M, *et al.* Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. *J Clin Endocrinol Metab* 2009;94:3306-13.
- Konradsen S, Ag H, Lindberg F, Hexeberg S, Jorde R. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. *Eur J Nutr* 2008;47:87-91.
- Snijder MB, van Dam RM, Visser M, Deeg DJ, Dekker JM, Bouter LM, *et al.* Adiposity in relation to vitamin D status and parathyroid hormone levels: A population-based study in older men and women. *J Clin Endocrinol Metab* 2005;90:4119-23.
- Ozata M, Durmus O, Yilmaz MI, Bolu E, Erdogan M, Ozdemir IC. The renin-angiotensin-aldosterone system (RAAS) and its relation with calcium homeostasis in male obesity. *Med Sci Monit* 2002;8:CR430-4.
- Çizmecioglu FM, Etiler N, Görmüş U, Hamzaoğlu O, Hatun Ş. Hypovitaminosis D in obese and overweight schoolchildren. *J Clin Res Pediatr Endocrinol* 2008;1:89-96.
- Ergür AT, Berberoğlu M, Atasay B, Şıklar Z, Bilir P, Arsan S, *et al.* Vitamin D deficiency in Turkish mothers and their neonates and in women of reproductive age. *J Clin Res Pediatr Endocrinol* 2009;1:266-9.
- Ustuner I, Keskin HL, Tas EE, Neselioglu S, Sengul O, Avsar AF. Maternal serum 25 (OH) D levels in the third trimester of pregnancy during the winter season. *J Matern Fetal Neonatal Med* 2011;24:1421-6.
- Hekimsoy Z, Dinç G, Kafesçiler S, Onur E, Güvenç Y, Pala T, *et al.* Vitamin D status among adults in the Aegean region of Turkey. *BMC Public Health* 2010;10:782.
- Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG, *et al.* Serum 25-hydroxyvitamin D concentrations in

- obese and non-obese women with polycystic ovary syndrome. *Arch Gynecol Obstet* 2009;280:559-63.
32. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357:266-81.
  33. Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, Lensmeyer G, *et al.* Low vitamin D status despite abundant sun exposure. *J Clin Endocrinol Metab* 2007;92:2130-5.
  34. Holick MF. Vitamin D. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. *Modern Nutrition in Health and Disease*. 10<sup>th</sup> ed. Baltimore MD: lippincott Williams and Wilkins; 2006. p. 900-930.
  35. Saintonge S, Bang H, Gerber LM. Implications of a new definition of vitamin D deficiency in a multiracial us adolescent population: The National Health and Nutrition Examination Survey III. *Pediatrics* 2009;123:797-803.
  36. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, *et al.* Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. *Am J Clin Nutr* 2002;76:187-92.
  37. Penckofer S, Kouba J, Wallis DE, Emanuele MA. Vitamin D and diabetes: Let the sunshine in. *Diabetes Educ* 2008;34(6):939-44
  38. Mathieu C, Gysemans C, Giuliotti A, Bouillon R. Vitamin D and diabetes. *Diabetologia* 2005;48:1247-57.
  39. Flores M. A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? *Nutr Res Rev* 2005;18:175-82.
  40. Al-Daghri NM, Al-Attas OS, Al-Okail MS, Alkharfy KM, Al-Yousef MA, Nadhrah HM, *et al.* Severe hypovitaminosis D is widespread and more common in non-diabetics than diabetics in Saudi adults. *Saudi Med J* 2010;31:775-80.
  41. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, *et al.* Strong association between non alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. *BMC Med* 2011; 12(9):85. .

**How to cite this article:** Cimbek A, Gürsoy G, Kirnap NG, Acar Y, Kiliç Z, Güngör F, *et al.* Relation of obesity with serum 25 hydroxy vitamin D3 levels in type 2 diabetic patients. *J Res Med Sci* 2012;17:1119-23

**Source of Support:** Nil, **Conflict of Interest:** None declared.